

Glencicimab does not impact glycoprotein VI-dependent inflammatory hemostasis


Soumaya Jadoui,^{1*} Ophélie Le Chapelain,^{1*} Véronique Ollivier,¹ Ali Mostefa-Kara,¹ Lucas Di Meglio,¹ Sébastien Dupont,¹ Angèle Gros,¹ Mialitiana Solo Nomenjanahary,¹ Jean-Philippe Desilles,^{1,2} Mikaël Mazighi,^{1,2} Bernhard Nieswandt,³ Stéphane Loyau,¹ Martine Jandrot-Perrus,¹ Pierre H. Mangin⁴ and Benoit Ho-Tin-Noé¹

¹Université de Paris, LVTS, INSERM U1148, Paris, France; ²Department of Interventional Neuroradiology, Rothschild Foundation Hospital, Paris, France; ³University Hospital Würzburg, Rudolf Virchow Center for Experimental Biomedicine, Würzburg, Germany and ⁴Université de Strasbourg, INSERM, EFS Grand-Est, BPPS UMR-S1255, FMTS, Strasbourg, France

*SJ and OLC contributed equally as co-first authors.

Correspondence: BENOIT HO-TIN-NOÉ' - benoit.ho-tin-noe@inserm.fr

doi:10.3324/haematol.2020.270439



Supplemental Figure 1. Impact of ACT017 on platelet-dependent prevention of tumor bleeding. Haemoglobin content and macroscopic aspect of B16F1 tumors from hGPVI mice treated or not with ACT017 (64 mg/kg) or a platelet-depleting antibody. Tumors were excised 8 hours after injection of the treatments. # indicates a significant difference ($p < 0.05$) from the hGPVI group, $n = 8-10$ tumors per group. Bar = 500 μm .

Supplemental Movie Legend. Citrated whole blood from hGPVI mice was labeled with the fluorochrome DiOC6, incubated or not with ACT017 (Glenzocimab, 80 $\mu\text{g/mL}$) for 10 min, and perfused at a wall shear rate of 1500 s^{-1} over a collagen-coated surface. The video shows the comparison of platelet deposition onto collagen in the presence or absence of Glenzocimab.